CFP
VRTX icon

Catalyst Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Catalyst Financial Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$739K Buy
1,654
+322
+24% +$150K 0.09% 141
2025
Q4 		$604K Buy
1,332
+218
+20% +$94K 0.07% 152
2025
Q3 		$436K Sell
1,114
-56
-5% -$23.4K 0.05% 186
2025
Q2 		$521K Sell
1,170
-191
-14% -$88K 0.06% 161
2025
Q1 		$660K Buy
1,361
+236
+21% +$110K 0.12% 115
2024
Q4 		$453K Buy
1,125
+39
+4% +$18.1K 0.09% 151
2024
Q3 		$505K Buy
1,086
+1
+0.1% +$480 0.1% 138
2024
Q2 		$509K Buy
1,085
+67
+7% +$29.1K 0.11% 122
2024
Q1 		$400K Buy
1,018
+41
+4% +$17.3K 0.1% 133
2023
Q4 		$398K Buy
977
+36
+4% +$13.3K 0.11% 122
2023
Q3 		$327K Buy
941
+71
+8% +$24.8K 0.11% 146
2023
Q2 		$306K Buy
870
+121
+16% +$40.8K 0.11% 138
2023
Q1 		$236K Buy
+749
New +$225K 0.1% 156

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Catalyst Financial Partners's VRTX Position: Q1 2026 in Review

Catalyst Financial Partners increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2026, buying an estimated $150K and bringing the position to 1,654 shares worth $739K. The position accounts for 0.09% of the portfolio, ranked #141.

Catalyst Financial Partners first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Catalyst Financial Partners held 1,654 shares of Vertex Pharmaceuticals worth $739K as of Q1 2026.
  • Catalyst Financial Partners bought 322 Vertex Pharmaceuticals shares in Q1 2026, an estimated $150K.
  • Vertex Pharmaceuticals made up 0.09% of Catalyst Financial Partners's portfolio in Q1 2026, its #141 holding.
  • Catalyst Financial Partners first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Catalyst Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.